<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878604</url>
  </required_header>
  <id_info>
    <org_study_id>MISP50469</org_study_id>
    <nct_id>NCT01878604</nct_id>
  </id_info>
  <brief_title>Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia</brief_title>
  <official_title>The Study of Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify new or novel genes which may impact on cholesterol level, and establish the
      relationship between those gene mutations with atherosclerosis, as well as responses to
      lipid-lowering drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To better understand the genetics basis for LDL-C elevation and develop an optimized
      lipid-lowering strategy, we propose to do the following studies:

        1. To establish a China HoFH registry, and collect DNA and blood samples from all available
           family members of each proband (pedigrees);

        2. To detect gene mutations known to cause FH and identify family suitable for future whole
           genome sequencing aimed to identify novel genes controlling cholesterol levels.

      3.To establish the relationship between types of gene mutations and lipid and atherosclerosis
      profile, as well as responses to lipid-lowering agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of LDLR Gene Mutations</measure>
    <time_frame>1 year</time_frame>
    <description>Number of gene mutations based on the sequencing results in terms of some known genes and suspected novel genes.
c.796 G&gt;C and c.1048 C&gt;T in the LDLR gene c.1448 G&gt;A and c.1720C&gt;A in the LDLR gene c.2030 G &gt;A and c.1257 C&gt;A in the LDLR gene homozygous mutation c.605 T&gt;C in the LDLR gene</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-C Reduction Percentage</measure>
    <time_frame>pre-treatment and 6-13 years post treatment</time_frame>
    <description>plasma LDL-C reduction percentage with lipid-lowering drugs from pre-treatment to the last time follow-up time point
plasma LDL-C reduction percentage calculation: &quot;plasma LDL-C at pre-treatment time point&quot; minus &quot;plasma LDL-C at the last time follow-up time point&quot;, and then compared with &quot;plasma LDL-C at pre-treatment time point&quot;, namely &quot;plasma LDL-C reduction percentage&quot;.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Homozygous Familial Hypercholesterolemia</arm_group_label>
    <description>Gene Analysis for Homozygous Familial Hypercholesterolemia cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Gene analysis</intervention_name>
    <description>Gene analysis</description>
    <arm_group_label>Homozygous Familial Hypercholesterolemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Historical data of lipid-lowering drug administration</intervention_name>
    <description>Collecting historical data of lipid-lowering drug administration</description>
    <arm_group_label>Homozygous Familial Hypercholesterolemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Historical data of plasma lipids, xanthoma changes</intervention_name>
    <description>Collecting historical data of plasma lipids and xanthoma changes</description>
    <arm_group_label>Homozygous Familial Hypercholesterolemia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Homozygous Familial Hypercholesterolemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients of any age and sex who meet clinical or genetic criteria for hoFH as follows:

          -  Cutaneous xanthomata before the age of ten years

          -  LDLC &gt; 13 mmol/L before treatment or &gt; 7.76 mmol/L despite treatment

          -  Phenotypic features in keeping with HeFH in both parents

        Exclusion criteria:

        Inability of patient, or, if less than 18, a parent, to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuiping Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology department of 2nd Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>February 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2017</results_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Shuiping Zhao</investigator_full_name>
    <investigator_title>Chief of Cardiology Department, 2nd Xiangya Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Homozygous Familial Hypercholesterolemia</title>
          <description>Gene Analysis for Homozygous Familial Hypercholesterolemia cases
Gene analysis: Gene analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients of HoFH</title>
          <description>patients of Homozygous Familial Hypercholesterolemia</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>plasma LDL cholesterol concentration</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.55" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of LDLR Gene Mutations</title>
        <description>Number of gene mutations based on the sequencing results in terms of some known genes and suspected novel genes.
c.796 G&gt;C and c.1048 C&gt;T in the LDLR gene c.1448 G&gt;A and c.1720C&gt;A in the LDLR gene c.2030 G &gt;A and c.1257 C&gt;A in the LDLR gene homozygous mutation c.605 T&gt;C in the LDLR gene</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HoFH Patients</title>
            <description>HoFH patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of LDLR Gene Mutations</title>
          <description>Number of gene mutations based on the sequencing results in terms of some known genes and suspected novel genes.
c.796 G&gt;C and c.1048 C&gt;T in the LDLR gene c.1448 G&gt;A and c.1720C&gt;A in the LDLR gene c.2030 G &gt;A and c.1257 C&gt;A in the LDLR gene homozygous mutation c.605 T&gt;C in the LDLR gene</description>
          <units>gene mutations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-C Reduction Percentage</title>
        <description>plasma LDL-C reduction percentage with lipid-lowering drugs from pre-treatment to the last time follow-up time point
plasma LDL-C reduction percentage calculation: &quot;plasma LDL-C at pre-treatment time point&quot; minus &quot;plasma LDL-C at the last time follow-up time point&quot;, and then compared with &quot;plasma LDL-C at pre-treatment time point&quot;, namely &quot;plasma LDL-C reduction percentage&quot;.</description>
        <time_frame>pre-treatment and 6-13 years post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HoFH Patients</title>
            <description>patients of Homozygous Familial Hypercholesterolemia that meet the Inclusion criteria:
Cutaneous xanthomata before the age of ten years
LDLC &gt; 13 mmol/L before treatment or &gt; 7.76 mmol/L despite treatment
Phenotypic features in keeping with HeFH in both parents</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-C Reduction Percentage</title>
          <description>plasma LDL-C reduction percentage with lipid-lowering drugs from pre-treatment to the last time follow-up time point
plasma LDL-C reduction percentage calculation: &quot;plasma LDL-C at pre-treatment time point&quot; minus &quot;plasma LDL-C at the last time follow-up time point&quot;, and then compared with &quot;plasma LDL-C at pre-treatment time point&quot;, namely &quot;plasma LDL-C reduction percentage&quot;.</description>
          <units>percentage of plasma LDL-C reduction</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.16" spread="8.5981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only serious adverse events were collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>HoFH Patients</title>
          <description>all HoFH patients enrolled in this study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shuiping Zhao</name_or_title>
      <organization>Central South University</organization>
      <phone>86-731-85295806</phone>
      <email>zhaosp@medmail.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

